<SEC-DOCUMENT>0001193125-24-166931.txt : 20240624
<SEC-HEADER>0001193125-24-166931.hdr.sgml : 20240624
<ACCEPTANCE-DATETIME>20240624160240
ACCESSION NUMBER:		0001193125-24-166931
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240624
DATE AS OF CHANGE:		20240624

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276774
		FILM NUMBER:		241064217

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d860433d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-276774</FONT></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated
February&nbsp;5, 2024) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>4,755,556 American Depositary Shares representing 47,555,560 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g860433g0622033928005.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February&nbsp;5, 2024 (the
&#147;Prospectus&#148;), which forms a part of our Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-276774),</FONT> with the information contained in our current
report on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> furnished to the Securities and Exchange Commission on June&nbsp;24, 2024 (the &#147;June 24, 2024 Form <FONT STYLE="white-space:nowrap">6-K&#148;).</FONT> Accordingly, we have attached the
June&nbsp;24, 2024 Form <FONT STYLE="white-space:nowrap">6-K</FONT> to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates and supplements the
information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction
with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are listed on The Nasdaq Capital Market (&#147;Nasdaq&#148;) under the symbol &#147;KZIA.&#148; On June&nbsp;21, 2024, the last reported sale price
of the ADSs on Nasdaq was $0.2676 per ADS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page
9 of the Prospectus and the &#147;Risk Factors&#148; in &#147;Item 3. Key Information&#151;D. Risk Factors&#148; of our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> which is incorporated by reference in the
Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal
offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is June&nbsp;24, 2024 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of June, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form</FONT> <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form
<FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&#8194;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appointment of Director </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Resignation of
Principal Financial and Accounting Officer; Appointment of Principal Accounting Officer and Principal Financial Officer </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
May&nbsp;16, 2024, Kazia Therapeutics Limited (the &#147;Company&#148;) received notice from Gabrielle Heaton of her intention to resign as the Company&#146;s Vice President, Finance and Administration, effective June&nbsp;28, 2024.
Ms.&nbsp;Heaton&#146;s resignation is not the result of any disagreement between Ms.&nbsp;Heaton and the Company, its management or board of directors, or related to the Company&#146;s operations, policies or practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;24, 2024, the Company&#146;s Board of Directors appointed Jeffrey Bonacorda as its Principal Accounting Officer and Principal
Financial Officer, effective July&nbsp;1, 2024. Mr.&nbsp;Bonacorda&#146;s annual base compensation will be $150,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Bonacorda
joined Kazia on May 13, 2024 and currently serves as the Company&#146;s Vice President, Finance and Controller. Mr&nbsp;Bonacorda is a senior accounting professional with more than 25 years of experience in the commercial pharmaceutical, consumer
products and service industries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein into the Company&#146;s
registration statements on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File Nos. <FONT STYLE="white-space:nowrap">333-259224</FONT> and <FONT STYLE="white-space:nowrap">333-276091).</FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia</B><B> Therape</B><B>utics Limited </B>(Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John Friend</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 24&nbsp;June 2024</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g860433g0622033928005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g860433g0622033928005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  [ -(# 2(  A$! Q$!_\0
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MN;\+3ZE,UP+PRM&,;3+G.?;-=)652'LY<IM0JJM!32M<**;(2L;,.H!->-^
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MV.AYZ&EN=/-S=PS-,0L3!PH49R/?K@]ZN44^>0.E!BT4E%0:"T4E% "T4E%
'"T4E% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
